Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2016 | short review

Treatment of elderly and very old patients with AML

verfasst von: Elisabeth Koller, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Acute Myeloid Leukemia (AML) is a genetically heterogeneous malignant disease mainly occurring in elderly patients. The prognosis of patients over 60 years of age, which represent the majority of patients, which are diagnosed, remains poor. The main reasons for the poor outcome are the in-creasing number of comorbidities, organ impairments and nevertheless the unfavorable genetic features, pre-existing myelodysplastic changes and rising multi-drug resistance. It is also more likely that older and frail patients are not included into clinical trials and treatment decisions have to be made on general assumptions.
Vorheriger Artikel Never too old to treat cancer?
Nächster Artikel Treatment of elderly patients with diffuse large B-cell lymphoma
Literatur
1.
Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendation of an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453–74.CrossRefPubMed
2.
Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136–52.CrossRefPubMed
3.
4.
Kantarjian H, O’Brian S, Cortes J, et al. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive models for outcome. Cancer. 2006;106(5):1090–98.CrossRefPubMed
5.
Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598–605.CrossRefPubMed
6.
Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myeloid leukemia. J Am Geriatr Soc 2011;59 (10):1837-46, 1245–51.CrossRef
7.
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT) specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–19.CrossRefPubMedPubMedCentral
8.
Giles FJ, Borthakur G, Ravandi F, Faderl S, et al. The hematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over the age of 60 receiving induction therapy for acute myeloid leukemia. Br J Haematol. 2007;136(4):624–27.CrossRefPubMed
9.
Savic A, Kvrgic V, Rajic N, et al. The hematopoietic cell transplantation index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36(4):479–82.CrossRefPubMed
10.
Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for chemotherapy. Cancer. 2007;109:1114–24.CrossRefPubMed
11.
Burnett AK, Russel NH, Hills RK, et al. Addition of gemtuzumab ozogamizin to induction chemotherapy improves survival in older patients with AML. J Clin Oncol. 2012;30(32):3924–31.CrossRefPubMed
12.
Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–7.CrossRefPubMed
13.
Fenaux P, Mufti GJ, et al. Azacytidine prolongs overall survival compared to conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9.CrossRefPubMed
14.
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with over 30 % blasts. Blood. 2015;126:291–9.CrossRefPubMedPubMedCentral
15.
Seymour JF, Döhner H, et al. Azacytidine versus conventional care regimens in older patients with newly diagnosed AML with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial. ASH annual meeting oral abstracts 2014.
Metadaten
Titel
Treatment of elderly and very old patients with AML
verfasst von
Elisabeth Koller, MD
Publikationsdatum
01.02.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0249-5

Weitere Artikel der Ausgabe 1/2016

Intensive care for cancer patients

  • Open Access
  • review

Erratum to: A review on biomolecular basis of the role of psychological stress in the development and progression of cancer

  • Erratum

8-year-sustained response in a patient with isolated del(5q) myelodysplastic syndrome undergoing continuous treatment with lenalidomide: a case report

  • case report

Parapharyngeal malignant peripheral nerve sheath tumor: a case report and review of the literature

  • case report

Treatment of elderly patients with melanoma

  • short review

Open Access publizieren in „memo – magazine of european medical oncology“

  • editorial